CLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026 in Snowbird, Utah. To request a meeting with Apyx, investors should contact their BTIG representatives. A ...

Core Viewpoint - Apyx Medical Corporation reported preliminary revenue results for Q4 and full year 2025, highlighting strong growth driven by the commercial launch of the AYON Body Contouring System and increased demand in the surgical aesthetics market [1][4]. Preliminary Fourth Quarter 2025 Revenue Summary - Total revenue for Q4 2025 is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year [7]. - Surgical Aesthetics revenue for Q4 2025 is expected to be in the range of approximately $16.6 to $16.8 million, reflecting an increase of approximately 38% year-over-year [7]. - OEM revenue for Q4 2025 is expected to be approximately $2.4 million, indicating an increase of approximately 13% year-over-year [7]. Preliminary Full Year 2025 Revenue Summary - Total revenue for the full year 2025 is expected to be in the range of approximately $52.7 to $52.9 million, representing an increase of approximately 10% year-over-year [7]. - Surgical Aesthetics revenue for the full year 2025 is expected to be in the range of approximately $45.2 to $45.4 million, showing an increase of approximately 17% year-over-year [7]. - OEM revenue for the full year 2025 is expected to be approximately $7.5 million, reflecting a decrease of 21% year-over-year [7]. Industry Context - The commercial launch of AYON has generated immediate momentum, contributing to a strong fourth quarter performance, with a noted increase in aesthetic surgical procedures in the U.S. driven by the adoption of GLP-1 therapies leading to significant patient weight loss [4]. - The company is positioned to capitalize on the positive industry momentum in the surgical aesthetics market [4]. Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion® and the AYON Body Contouring System™ [5]. - The AYON Body Contouring System is an FDA-cleared, surgeon-designed platform that integrates various capabilities for comprehensive body contouring treatments [5]. - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical documents, showcasing the company's commitment to innovation in the cosmetic surgery market [5].

Core Insights - Apyx Medical Corporation has received regulatory approval for the Apyx One console and plans to launch commercial sales in South Korea, with initial orders expected in Q4 2025 [1][3] - The Apyx One console features a 3-in-1 energy system that allows for advanced surgical procedures, including Renuvion technology, and is designed for ease of use with adaptive touch screens and energy quantification [2] - The cosmetic surgery market in South Korea is projected to grow from $1.7 billion in 2024 to over $3.9 billion by 2033, indicating a significant opportunity for Apyx Medical's body contouring technology [3] Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering innovative products such as Renuvion and the AYON Body Contouring System, which provide controlled heat to tissue for surgical procedures [4] - The AYON Body Contouring System is FDA-cleared and designed to integrate multiple surgical capabilities, enhancing the versatility and precision of body contouring treatments [4]

Core Viewpoint - Apyx Medical Corporation is initiating an underwritten public offering of its common stock, subject to market conditions, with no assurance on the completion or terms of the offering [1]. Group 1: Offering Details - Lucid Capital Markets is the sole book-running manager for the offering [2]. - The offering is made under a shelf registration statement filed with the SEC on November 22, 2022, and declared effective on December 2, 2022 [2]. Group 2: Company Overview - Apyx Medical Corporation specializes in surgical aesthetics, offering products like Renuvion and the AYON Body Contouring System, which are designed to enhance surgical outcomes [5]. - The Renuvion and J-Plasma technologies provide controlled heat to tissue, supported by over 90 clinical documents [5]. - The AYON Body Contouring System is FDA-cleared and integrates multiple capabilities for comprehensive body contouring treatments [5].

Core Insights - Apyx Medical Corporation is set to participate in two upcoming investor conferences, showcasing its proprietary technologies [1][2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as Renuvion and the AYON Body Contouring System™ [3] - Renuvion and J-Plasma technologies provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The AYON Body Contouring System™ is an FDA-cleared platform that integrates multiple capabilities for comprehensive body contouring treatments [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Core Viewpoint - Apyx Medical Corporation will release its financial results for the third quarter of fiscal year 2025 on November 6, 2025, before market opening [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 8:00 a.m. Eastern Time on the same day [2] - Interested parties can join the call by dialing 800-717-1738 or 646-307-1865 for international callers, using access code 73607 [2] - A live webcast of the call will be available and archived on the company's Investor Relations website [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and the AYON Body Contouring System™ [3] - The company’s Helium Plasma Platform Technology products are utilized in both cosmetic surgery and hospital surgical markets [3] - Renuvion and J-Plasma provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical publications [3] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Core Insights - Apyx Medical Corporation has initiated the nationwide commercial launch of the AYON Body Contouring System, with a focus on expanding its capabilities to include power liposuction through a new 510(k) premarket notification to the FDA [2][3] - The AYON system is designed to integrate various body contouring procedures into a single platform, enhancing workflow for surgeons and potentially improving patient outcomes [3][5] - Apyx Medical is hosting a virtual event on October 14, 2025, featuring key opinion leaders to discuss the commercial launch and advancements of the AYON system [4] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, particularly in the cosmetic surgery market with products like Renuvion and the AYON Body Contouring System [5] - The AYON Body Contouring System is FDA-cleared and combines multiple functionalities, including fat removal and tissue contraction, aimed at providing comprehensive body contouring treatments [5] - The company has received positive feedback from early adopters of the AYON system, indicating strong market interest and potential for growth [3]

Core Insights - Apyx Medical Corporation announced a virtual key opinion leader event to discuss the commercial launch of its new AYON Body Contouring System on October 14, 2025 [1] - The AYON Body Contouring System is the first FDA cleared all-in-one platform for aesthetic surgical suites, integrating multiple capabilities for improved surgical outcomes [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and AYON in the cosmetic surgery market [5] - The company’s Renuvion and J-Plasma technologies provide controlled heat to tissue, supported by over 90 clinical publications [5] Key Opinion Leader Event - The event will feature Dr. Paul Vanek, a renowned plastic surgeon, who will discuss the AYON Body Contouring System alongside company management [1][2] - A live Q&A session will follow the formal presentations, allowing for direct engagement with attendees [3] Product Features - The AYON Body Contouring System combines precision, versatility, and innovation, designed to streamline procedures and maximize patient outcomes [2] - It integrates fat removal, closed loop contouring, tissue contraction, and electrosurgical capabilities, setting a new standard in surgical care [2] Leadership Profile - Dr. Paul Vanek is recognized for his extensive experience in the field, having built a successful practice and contributed to various medical innovations [4] - He has held leadership roles in hospital systems and has been involved in numerous philanthropic efforts [4]

Core Points - Apyx Medical Corporation granted a nonstatutory stock option to John Featherstone, Vice President of North American Sales, for 100,000 shares as an inducement for employment [1][2] - The stock option has an exercise price of $1.85, which is the closing price of Apyx Medical's common stock on the grant date [2] - The stock option vests over a four-year period, with 25% vesting on the first anniversary and the remainder vesting annually, contingent on continued employment [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion and AYON Body Contouring System in the cosmetic surgery market, and J-Plasma in the hospital surgical market [3] - Renuvion and J-Plasma provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as Renuvion® and the AYON Body Contouring System™ for the cosmetic surgery market, as well as J-Plasma® for the hospital surgical market [3] - The company's technologies provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical publications [3] Upcoming Events - Management will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, MA [1] - The President and CEO, Charlie Goodwin, along with CFO, Matt Hill, will engage in a fireside chat at 4:00 PM ET and will hold one-on-one meetings with investors throughout the day [2] Investor Relations - For further inquiries, the investor relations contact is Jeremy Feffer, Managing Director at LifeSci Advisors, reachable at 212-915-2568 or via email [4]